MX2019008317A - Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico. - Google Patents

Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.

Info

Publication number
MX2019008317A
MX2019008317A MX2019008317A MX2019008317A MX2019008317A MX 2019008317 A MX2019008317 A MX 2019008317A MX 2019008317 A MX2019008317 A MX 2019008317A MX 2019008317 A MX2019008317 A MX 2019008317A MX 2019008317 A MX2019008317 A MX 2019008317A
Authority
MX
Mexico
Prior art keywords
liver disease
fatty liver
nonalcoholic fatty
prophylactic
therapeutic drug
Prior art date
Application number
MX2019008317A
Other languages
English (en)
Inventor
Sasaki Yusuke
Tanaka Toshiya
ASAHIYAMA Masato
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MX2019008317A publication Critical patent/MX2019008317A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención aborda el problema de proporcionar una composición medicinal y una combinación de fármacos mediante la cual puede prevenirse y/o tratarse enfermedad de hígado graso no alcohólico y esteatohepatitis no alcohólica. La presente invención proporciona una combinación de un agonista de receptor activado por proliferador de peroxisoma a con un inhibidor de cotransportador 2 de glucosa de sodio (SGLT2), la cual va a ser usada para prevenir y/o tratar enfermedad de hígado graso no alcohólico y esteatohepatitis no alcohólica.
MX2019008317A 2017-01-11 2018-01-11 Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico. MX2019008317A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017002731 2017-01-11
PCT/JP2018/000398 WO2018131626A1 (ja) 2017-01-11 2018-01-11 非アルコール性脂肪性肝疾患の予防及び治療薬

Publications (1)

Publication Number Publication Date
MX2019008317A true MX2019008317A (es) 2019-09-19

Family

ID=62840012

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008317A MX2019008317A (es) 2017-01-11 2018-01-11 Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.
MX2022015500A MX2022015500A (es) 2017-01-11 2019-07-10 Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022015500A MX2022015500A (es) 2017-01-11 2019-07-10 Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.

Country Status (10)

Country Link
US (3) US20200022960A1 (es)
EP (1) EP3569250A4 (es)
JP (2) JP7202892B2 (es)
KR (1) KR102487075B1 (es)
CN (1) CN110167595A (es)
AU (1) AU2018206907B2 (es)
BR (1) BR112019013539A2 (es)
CA (1) CA3047716A1 (es)
MX (2) MX2019008317A (es)
WO (1) WO2018131626A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202103552XA (en) 2015-03-09 2021-05-28 Intekrin Therapeutics Inc Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
MX2021008010A (es) * 2018-12-31 2021-10-13 Coherus Biosciences Inc Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).
WO2020205027A1 (en) * 2019-04-02 2020-10-08 Christos Mantzoros Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
CN117677385A (zh) 2021-05-27 2024-03-08 兴和株式会社 用于治疗肝病的培马贝特和/或托格列净

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1609785T3 (pl) 2003-03-14 2016-07-29 Astellas Pharma Inc Pochodne c-glikozydowe i ich sole
KR100515360B1 (ko) 2003-09-02 2005-09-15 삼성에스디아이 주식회사 플라즈마 표시 패널 및 그의 구동 방법
PL1661890T3 (pl) 2003-09-03 2011-06-30 Kowa Co Związek aktywujący PPAR oraz kompozycja farmaceutyczna zawierająca ten związek
ES2581331T3 (es) 2004-07-21 2016-09-05 Kissei Pharmaceutical Co., Ltd. Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
KR20150005365A (ko) 2013-07-05 2015-01-14 에스케이하이닉스 주식회사 주기신호생성회로
TWI696462B (zh) 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
MX2017003944A (es) 2014-09-25 2017-06-26 Astrazeneca Ab Combinacion de un acido graso omega-3 y un inhibidor de sglt-2 para tratar enfermedades hepaticas.

Also Published As

Publication number Publication date
RU2019123735A3 (es) 2021-03-26
CA3047716A1 (en) 2018-07-19
EP3569250A1 (en) 2019-11-20
CN110167595A (zh) 2019-08-23
US20200022960A1 (en) 2020-01-23
JP2023024728A (ja) 2023-02-16
MX2022015500A (es) 2023-01-24
AU2018206907A1 (en) 2019-07-11
BR112019013539A2 (pt) 2020-01-07
KR20190104542A (ko) 2019-09-10
WO2018131626A1 (ja) 2018-07-19
US12042483B2 (en) 2024-07-23
US20240325356A1 (en) 2024-10-03
RU2019123735A (ru) 2021-02-12
US20220054459A1 (en) 2022-02-24
AU2018206907B2 (en) 2023-11-02
JP7202892B2 (ja) 2023-01-12
EP3569250A4 (en) 2020-11-04
JPWO2018131626A1 (ja) 2019-11-07
KR102487075B1 (ko) 2023-01-09

Similar Documents

Publication Publication Date Title
MX2019008317A (es) Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
MX2020014315A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington.
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
MX2024001205A (es) Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con compuestos antifibroticos para usarse en tratar enfermedades del higado graso.
AR071003A1 (es) Farmaco contra cancer de higado
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
MX2017010544A (es) Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
EP4364804A3 (en) Inhibitors of keap1-nrf2 protein-protein interaction
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
MA39443A1 (fr) Nouvelle formulation de méloxicam
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
MX2021000700A (es) Composicion farmaceutica para prevenir o tratar esteatohepatitis no alcoholica.
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
CL2019000625A1 (es) Combinación de agonistas de fxr.
MX2019014665A (es) Nuevos derivados de azaindolina sustituida como inhibidores de nik.
PL1951692T3 (pl) Oksazolowe i tiazolowe modulatory PPAR
BR112017013845A2 (pt) derivados de glucagon
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MY196680A (en) Ethanesulfonate salt of n-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2- pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3- quinolinecarboxamide
EP4017880A4 (en) USE OF BRAZIKUMAB TO TREAT CROHN'S DISEASE